Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.

Inclusion Criteria:

• Diagnosis of Multiple Sclerosis according to 2010 revised McDonald criteria
• Disease duration of 10 years or less
• At least one relapse in the last year
• EDSS score 0 to 5.0 at entry

Exclusion Criteria:

• Active chronic disease of the immune system other than multiple sclerosis
• History of malignancy within the past 5 years
• Active systemic bacterial, viral or fungal infections
• Previous treatment with more than one class of multiple sclerosis therapies except for previous treatment with glatiramer acetate and interferon-beta(s)
• Any medically unstable condition
• Unable to undergo MRI scans or repeated blood tests
• Pregnant or nursing females
• Women of child-bearing potential must use reliable forms of contraception
• Other protocol-defined inclusion/exclusion criteria may apply.